Dendreon Corp (DNDN)

0.06
0.00 6.02
NASDAQ : Health Care
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.04 / 3.46
Volume 1.37M
Avg Volume 5.11M
Exchange NASDAQ
Shares Outstanding 158.72M
Market Cap 20.16M
EPS -1.95
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices

A debate about NPS Pharma, Gattex and the sustainability of orphan drug pricing with Forbes' Matt Herper

Dendreon Sells New Jersey Immunotherapy Manufacturing Facility

Dendreon Sells New Jersey Immunotherapy Manufacturing Facility

Dendreon Corporation (NASDAQ: DNDN) today announced the sale of its immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corporation for $43 million in cash.

Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study

Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study

Stimuvax failed to prolong survival in a large study of lung cancer patients.

The Worst Biotech CEO of 2012 Is...

The Worst Biotech CEO of 2012 Is...

Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.

Dendreon Announces Webcast Presentations At Upcoming Conferences

Dendreon Announces Webcast Presentations At Upcoming Conferences

November 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: 2012 dbAccess BioFEST in Boston, MA, on December 4, 2012, at 2:15 p.

Dendreon Appoints Lindsay Rocco To Lead Corporate Communications

Dendreon Appoints Lindsay Rocco To Lead Corporate Communications

Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of Lindsay Rocco as executive vice president, corporate communications and member of the executive committee, effective immediately.

Dendreon: No-Drama Quarter Seen As Big Win

Dendreon: No-Drama Quarter Seen As Big Win

Provenge sales were light but no blowups left investors happier about Dendreon's future.

Dendreon Announces Third Quarter 2012 Results

Dendreon Announces Third Quarter 2012 Results

November 2, 2012 – Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2012.

Medivation Prostate Cancer Drug Launches Hot

Medivation Prostate Cancer Drug Launches Hot

Medivation's Xtandi jumps out of the launch gate with strong sales of $14 million.

Biotech Earnings Preview: Vertex, Dendreon, Incyte, Medivation, Onyx (Updated)

Biotech Earnings Preview: Vertex, Dendreon, Incyte, Medivation, Onyx (Updated)

Third-quarter earnings announcements have been rescheduled due to Hurricane Sandy.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet columnist Adam Feuerstein takes your biotech investing questions.

Dendreon Reschedules Third Quarter 2012 Results To November 2 Due To Hurricane Sandy

Dendreon Reschedules Third Quarter 2012 Results To November 2 Due To Hurricane Sandy

October 29, 2012–Dendreon Corporation (Nasdaq: DNDN) today announced that in light of Hurricane Sandy, the Company has rescheduled the release of its third quarter 2012 earnings results.

Biotech Earnings Preview: Vertex, Onyx, Dendreon, Medivation

Biotech Earnings Preview: Vertex, Onyx, Dendreon, Medivation

A busy week for biotech earnings includes the first look at cancer drug launches from Onyx and Medivation.

Dendreon To Host Conference Call On October 30 To Announce Third Quarter Financial Results And Webcast Presentations At Upcoming Conferences

Dendreon To Host Conference Call On October 30 To Announce Third Quarter Financial Results And Webcast Presentations At Upcoming Conferences

October 5, 2012–Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Tuesday, October 30, 2012, at 9:00 a.

Dendreon To Present At 3rd Annual Cancer Immunotherapy Conference In New York

Dendreon To Present At 3rd Annual Cancer Immunotherapy Conference In New York

October 3, 2012 – Dendreon Corporation (NASDAQ:DNDN) today announced the company will be presenting at the MD Becker Partners’ 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking ...

First Patient In Dendreon EU Open-Label Study Begins Sipuleucel-T Infusion Treatment

First Patient In Dendreon EU Open-Label Study Begins Sipuleucel-T Infusion Treatment

September 27, 2012--Dendreon Corporation (NASDAQ: DNDN) today announced the first patient enrollment and initiation of treatment for the sipuleucel-T European Union (EU) open-label study.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

How To Trade Peregrine Pharma For Profits

How To Trade Peregrine Pharma For Profits

Biotech trader Dan Rosenblum shows how to trade a controversial stock even if you lack strong conviction.

Cramer's 'Mad Money' Recap: A Rally Based on Facts

Cramer's 'Mad Money' Recap: A Rally Based on Facts

Cramer says he's no longer afraid of the future.

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

More data will help Peregrine convince skeptics that bavituximab is a real lung cancer drug.

Dendreon Announces Webcast Presentations At Upcoming Conferences

Dendreon Announces Webcast Presentations At Upcoming Conferences

August 24, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: Stifel Nicolaus 2012 Global Healthcare Conference in Boston, MA, on ...

The 5 Dumbest Things on Wall Street This Week: Aug. 3

The 5 Dumbest Things on Wall Street This Week: Aug. 3

Twits. Prostate problems. Rogue comments by a UBS CEO and booted GM marketing honchos: It's time for this week's edition of Wall Street's dumbest.

The 5 Dumbest Things on Wall Street: August 3

The 5 Dumbest Things on Wall Street: August 3

Here is this week's roundup of the dumbest actions on Wall Street.

7 Hot Stocks to Trade (or Not)

7 Hot Stocks to Trade (or Not)

Here's a look at the technicals of some of the most actively traded stocks on the market today.

Dendreon's Provenge Problems Reach Terminal Stage

Dendreon's Provenge Problems Reach Terminal Stage

Provenge demand is slacking and no manner of cost cuts will bring Dendreon back from the precipice.

Cramer's Six Stocks in 60 Seconds: LNKD VLO HUM DNDN MAS STX

Cramer's Six Stocks in 60 Seconds: LNKD VLO HUM DNDN MAS STX

There's a lot not to like about most social media companies, Cramer said.

Dendreon Stock Gaps Down On Today's Open (DNDN)

Dendreon Stock Gaps Down On Today's Open (DNDN)

Shares of Dendreon (Nasdaq:DNDN) were gapping down Tuesday morning with an open price 18.6% lower than Monday's closing price. The stock closed at $6.18 yesterday and opened today's trading at $5.03.

Dendreon's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dendreon's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dendreon's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dendreon Announces Strategic Restructuring To Accelerate Path To Profitability And Future Growth

Dendreon Announces Strategic Restructuring To Accelerate Path To Profitability And Future Growth

July 30, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced a strategic restructuring plan designed to accelerate the Company’s path to profitability and future growth.